ALLO-501/501A
Relapsed/Refractory Non-Hodgkin Lymphoma (r/r NHL)
Phase 1Completed
Key Facts
Indication
Relapsed/Refractory Non-Hodgkin Lymphoma (r/r NHL)
Phase
Phase 1
Status
Completed
Company
About Allogene Therapeutics
Allogene Therapeutics is a clinical-stage biotech aiming to lead the next revolution in cell therapy with its AlloCAR T platform, designed to deliver scalable, on-demand treatments. The company has advanced a portfolio into Phase 2, with key catalysts in 2026, including the pivotal ALPHA3 trial in frontline large B-cell lymphoma. Its strategy leverages multiplex gene-editing and a proprietary lymphodepletion regimen to enable safe, effective, and commercially viable allogeneic therapies.
View full company profile